Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...
Complex genomic rearrangements (CGRs) involve large-scale genomic alterations with multiple breakpoints and are implicated in genetic diseases such as malformation syndromes, intellectual disability ...
The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease. However, researchers have now shown that there is a risk of inadvertently ...